drug_type
RELEVANT_DRUG
intervention_type
Bispecific T‑cell engager (BiTE) antibody
drug_description
A bispecific T‑cell engager (BiTE) antibody that simultaneously binds CD3 on T cells and CD19 on B‑lineage cells to redirect cytotoxic T cells to kill CD19+ B cells, depleting autoreactive B cells and reducing pathogenic autoantibodies.
nci_thesaurus_concept_id
C62528
nci_thesaurus_preferred_term
Blinatumomab
nci_thesaurus_definition
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.
drug_mesh_term
Blinatumomab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific T‑cell engager antibody that binds CD3 on T cells and CD19 on B‑lineage cells, bringing them into proximity to trigger cytotoxic T‑cell–mediated killing of CD19+ B cells, thereby depleting autoreactive B cells and reducing pathogenic autoantibodies.
drug_name
Blinatumomab
nct_id_drug_ref
NCT06684184